Juul seeks to extend stay on FDA ban, saying agency did not evaluate all its evidence

Juul seeks to extend stay on FDA ban, saying agency did not evaluate all its evidence


A sign advertising Juul brand vaping products is seen outside a shop in New York City, February 6, 2019.

Mike Segar | Reuters

Juul Labs is seeking to extend a temporary stay on the Food and Drug Administration’s ban of its e-cigarettes, according to a court filing Tuesday.

Juul said in the filing that the agency overlooked more than 6,000 pages of data that it provided about the aerosols generated by heating the liquid in its pods and that users ultimately inhale. The FDA had said last week the company’s application for market approval gave insufficient or conflicting data about the potential risks of using its products, including whether potentially harmful chemicals could leak out of the Juul pods.

A representative for the FDA declined to comment on the filing, saying the agency does not comment on ongoing litigation.

“Had FDA done a more thorough review (like it did for other applicants), it would have seen data showing that those chemicals are not observable in the aerosol that JUUL users inhale,” the company said in the filing with the U.S. District Court of Appeals for the District of Columbia Circuit.

Juul also cited a “backdrop of immense political pressure” that it said influenced the FDA’s decision. It said in its filing that taking its products off store shelves, even temporarily, would permanently damage its brand and that its customers would either use competitors’ products or return to traditional cigarettes.

Over the last year, rival e-cigarette makers British American Tobacco and NJOY have won approvals from the FDA for their e-cigarettes, although the agency rejected some of the flavored products submitted by those companies. The agency said it approved those companies’ tobacco-flavored products because they proved they could benefit adult smokers and outweighed the risk to underage users.

Juul had been the market leader in e-cigarettes since 2018, according to Euromonitor International. As of 2020, the company held 54.7% share of the $9.38 billion U.S. e-vapor market.

The company said that no other rival had their application denied for similar reasons and that the FDA offered no explanation for why it held Juul to a different standard. Juul had been seeking approval for its vaping device and tobacco- and menthol-flavored pods.

Last Thursday, the FDA denied to authorize the products and said the company had to stop selling its products effective immediately. The next day, the Columbia Circuit Court of Appeals granted the emergency request for a stay, pending its appeal of the decision.



Source

Healthy Returns: A key step forward for Novo Nordisk’s GLP-1 pill
Health

Healthy Returns: A key step forward for Novo Nordisk’s GLP-1 pill

Novo Nordisk flags flutter outside their office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, July 14, 2025. Tom Little | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. A closely watched pill from […]

Read More
Why U.S. cattle ranchers say Trump’s Argentine beef import talk is no solution to domestic food supply threat
Health

Why U.S. cattle ranchers say Trump’s Argentine beef import talk is no solution to domestic food supply threat

Cattle detained in the pens of the Chihuahua Regional Livestock Union , at the Jeronimo-Santa Teresa border crossing in Ciudad Juarez, Mexico on November 27, 2024, after the United States stopped imports of Mexican cattle due to the presence of screwworm. Anadolu | Anadolu | Getty Images Cattle ranchers in Texas and around the country […]

Read More
Anthropic launches Claude Life Sciences to give researchers an AI efficiency boost
Health

Anthropic launches Claude Life Sciences to give researchers an AI efficiency boost

Dario Amodei, Anthropic CEO, speaking on CNBC’s Squawk Box outside the World Economic Forum in Davos, Switzerland on Jan. 21st, 2025. Gerry Miller | CNBC Anthropic on Monday announced Claude for Life Sciences, a new offering for researchers to use the company’s artificial intelligence technology in the advancement of scientific discovery.  Claude for Life Sciences is […]

Read More